Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Jit

Showing results (1-10 of 407) with videos related to

Pageof 41
Sort By:
Journal of the National Cancer Institute|February 8, 2026
Human papillomavirus, human immunodeficiency virus, and the shared road to cervical cancer eliminationMark Jit
The Lancet. Infectious Diseases|September 13, 2015
High-dose influenza vaccines make economic sense for older peopleMark Jit
The Journal of Infection|May 4, 2010
The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysisMark Jit
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 12, 2021
Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018Mark Jit
Cost Effectiveness and Resource Allocation : C/E|November 21, 2018
MCDA from a health economics perspective: opportunities and pitfalls of extending economic evaluation to incorporate broader outcomesMark Jit
The Lancet. Infectious Diseases|April 20, 2016
The economic burden of dengue: no longer invisible or unavoidableMark Jit
Elife|December 15, 2012
Enzymes provide demographers with food for thoughtMark Jit, Patrick Gerland
Applied Health Economics and Health Policy|February 3, 2016
Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?Mark Jit, Raymond Hutubessy
Pharmacoeconomics|April 21, 2011
Modelling the epidemiology of infectious diseases for decision analysis: a primerMark Jit, Marc Brisson
Sexual Health|August 20, 2010
A brief history of economic evaluation for human papillomavirus vaccination policyPhilippe Beutels, Mark Jit
Pageof 41

Showing results (1-10 of 407) with videos related to

Sort By:
Pageof 41
Journal of the National Cancer Institute|February 8, 2026
Human papillomavirus, human immunodeficiency virus, and the shared road to cervical cancer eliminationMark Jit
The Lancet. Infectious Diseases|September 13, 2015
High-dose influenza vaccines make economic sense for older peopleMark Jit
The Journal of Infection|May 4, 2010
The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysisMark Jit
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 12, 2021
Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018Mark Jit
Cost Effectiveness and Resource Allocation : C/E|November 21, 2018
MCDA from a health economics perspective: opportunities and pitfalls of extending economic evaluation to incorporate broader outcomesMark Jit
The Lancet. Infectious Diseases|April 20, 2016
The economic burden of dengue: no longer invisible or unavoidableMark Jit
Elife|December 15, 2012
Enzymes provide demographers with food for thoughtMark Jit, Patrick Gerland
Applied Health Economics and Health Policy|February 3, 2016
Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?Mark Jit, Raymond Hutubessy
Pharmacoeconomics|April 21, 2011
Modelling the epidemiology of infectious diseases for decision analysis: a primerMark Jit, Marc Brisson
Sexual Health|August 20, 2010
A brief history of economic evaluation for human papillomavirus vaccination policyPhilippe Beutels, Mark Jit
Pageof 41